Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I4T-MC-JVCZ ramucirumab dose comparison in second-line metastatic gastric/GEJ cancer
2014-005067-32Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and gastric cancer (GC) (3 arms), sponsored by Eli Lilly and Company. Started Jun 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on 2014-005067-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005067-32.